Mandate

Vinge advises Lantmännen in connection with its acquisition of the Vaasan Group

January 15, 2015

Vinge advises Lantmännen Ek För (”Lantmännen”) in connection with its acquisition of the Vaasan Group (”Vaasan”) from Lion Capital. In 2013, Vaasan had net sales of approx. MEUR 415 and in total approx. 2,745 employees. Vaasan is engaged in the baking industry in the Nordic and Baltic regions and is a worldwide supplier of thin crisp and crisp bread. The purchase price is confidential. The transaction is conditional upon approval by the relevant competition authorities.

Vinge’s team consists of responsible partner Christina Kokko, partner Jonas Johansson and associates Sofie Bjärtun and Alex Miler. Associate Malin Malm has advised on IP matters, Matilda Gustafsson and Johan Cederblad have advised on environmental and real property matters, Anders Morén has advised on financing matters and Sara Strandberg has advised on employment law. Partner Marcus Glader and associates Grant McKelvey, Emil Fahlén Godö, Johan Wahlbom and Victoria Grossmann are advising on the competition law aspects of the transaction.

Vinge has also coordinated the work performed by Castrén & Snellman (Finland), Lawin (Estonia, Latvia and Lithuania), Haavind (Norway), Bech-Bruun (Denmark) and Heuking Kühn Lüer Wojtek (Germany).

Related

Vinge advised Precise Biometrics

Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026